ArticleBMC infectious diseases2026
Delayed diagnosis of patients with rifampicin-resistant tuberculosis and its associated factors in a high tuberculosis endemic area Guizhou, China.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundRifampicin-resistant tuberculosis (RR-TB) threatens global TB control; diagnostic delays worsen transmission and outcomes. Evidence on delays in high-burden settings is limited. This study quantified patient, health-system, and total diagnostic delays among RR-TB patients in Guizhou Province, China (2019-2023) and identified factors associated with prolonged delays to inform targeted control measures.
methodsWe included 2,677 RR-TB patients diagnosed and registered in Guizhou from 2019 to 2023. The status of three types of delays at different levels was investigated. Group comparisons used chi-square tests; temporal trends were evaluated with chi-square trend tests. Binary logistic regression models identified independent predictors of prolonged delays at multiple cutoffs.
resultsMedian delays were 32 days (IQR 3-118) for patient delay, 15 days (IQR 2-62) for health system delay, and 86 days (IQR 32-261) for total delay. From 2019 to 2023, health system and total delay rates declined significantly (P < 0.05), whereas patient delay rates showed no significant temporal change (P > 0.05). At a 14-day cutoff, patient delay was highest in Qianxinan Prefecture (75.0%, P < 0.05); health system and total delay rates were highest in Qiandongnan Prefecture (73.7% and 88.9%, respectively; P < 0.05). Multivariable analysis indicated that referral/recommend (OR = 1.44), comorbidities (OR = 1.51), initial treatment failure (OR = 1.32), and combined extrapulmonary TB (OR = 1.50) were independently associated with patient delay > 14 days; returned patients (OR = 1.84) and other registration classifications (OR = 1.39) predicted delays > 60 days. For health system delay, students (OR = 1.73) and migrant populations (OR = 3.39) had an increased risk at > 14 days, while initial treatment failure (OR = 1.45) and other registration classifications (OR = 1.98) were significant at > 60 days. For total delay, migrant populations (OR = 1.90), comorbidities (OR = 1.34), initial treatment failure (OR = 1.94), and other registration classifications (OR = 1.51) were key predictors.
conclusionAlthough progress has been made in reducing diagnostic delays for RR-TB in Guizhou Province, rising patient delay rates and significant regional disparities persist. Strengthening primary healthcare capacity, establishing active tracing and follow-up mechanisms, optimizing migrant population management, implementing revisit reminders for patients with initial treatment failure, and accelerating the deployment of molecular drug susceptibility testing are recommended to enhance early diagnosis and treatment outcomes, thereby advancing the global goal of ending tuberculosis by 2035. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.